Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab
- Katherine Van Loon
- , Anne M. Espinoza
- , David R. Fogelman
- , Robert A. Wolff
- , Milind M. Javle
- , Renuka V. Iyer
- , Vincent J. Picozzi
- , Ludmila Katherine Martin
- , Tanios Bekaii-Saab
- , Margaret A. Tempero
- , Nathan R. Foster
- , George P. Kim
- , Andrew H. Ko
Research output: Contribution to journal › Article › peer-review
6
!!Link opens in a new tab
Scopus
citations